Company / Return on Equity (ROE)
PharmaCyte Biotech, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
1.2%
FY2025
5-year range
-75.2% / 1.2%
FY2021-FY2025
Trend
+120.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -350.4% in FY2016 to 1.2% in FY2025.
Based on SEC 10-K filings.
1.2% in FY2025 with a 5-year CAGR of +81.9%.
Improved from -4.7% to 1.2% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +54.4pp
- 5-Year Change
- +81.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 120.4% year-over-year.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 1.2% | +120.4% |
| FY2024 | -5.9% | -26.1% |
| FY2023 | -4.7% | +91.1% |
| FY2022 | -53.2% | +29.3% |
| FY2021 | -75.2% | +6.8% |
| FY2020 | -80.7% | +31.8% |
| FY2019 | -118.4% | -115.4% |
| FY2018 | -54.9% | +40.9% |
| FY2017 | -93.0% | +73.5% |
| FY2016 | -350.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026